{"id":2612,"date":"2016-07-12T18:11:00","date_gmt":"2016-07-12T18:11:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2612"},"modified":"2020-11-25T22:41:49","modified_gmt":"2020-11-25T22:41:49","slug":"is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece","status":"publish","type":"post","link":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece\/","title":{"rendered":"Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece"},"content":{"rendered":"\n<div class=\"wp-block-image\"><figure class=\"alignleft size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"75\" height=\"97\" src=\"https:\/\/cdafound.org\/wp-content\/uploads\/2020\/11\/36-1-e1604513653940.gif\" alt=\"Journal Cover\" class=\"wp-image-2614\"\/><\/figure><\/div>\n\n\n\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27403912\">Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. J Gastroenterol Hepatol. 2017 Feb;32(2):466-472. doi: 10.1111\/jgh.13485. PMID: 27403912.<\/a><\/p>\n\n\n\n<br>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Summary<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Background &amp; Aim<\/h3>\n\n\n\n<p>The treatment of hepatitis C (HCV) with interferon (IFN)-free Direct-Acting Antivirals (DAAs) is anticipated to change the future burden of disease. Aim of this study is to quantify the impact of IFN-free DAAs on HCV-related morbidity and mortality in Greece under different scenarios concerning treatment coverage and primary prevention, including the proposed by World Health Organization Global Hepatitis Strategy. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Methods<\/h3>\n\n\n\n<p>A previously described model was used to project the future disease burden up to 2030 under scenarios which includes treatment based on the combination of pegylated-IFN with ribavirin (base case) and scenarios using DAAs therapies. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Results<\/h3>\n\n\n\n<p>Under the base case scenario, an increase in HCV-related morbidity and mortality is predicted in Greece (mortality in 2030: +23.6% compared to 2015). If DAAs are used with the same treatment coverage, the number of hepatocellular carcinoma cases and of liver related deaths are predicted to be lower by 4%-7% compared to 2015. Under increased treatment coverage (from 2,000 treated\/year to approximately 5,000\/year in 2015-2020 and 2,500\/year subsequently), morbidity and mortality will decrease by 43%-53% in 2030 compared to 2015. To achieve the WHO Global Hepatitis Strategy goals, a total number of 86,500 chronic hepatitis C patients will have to be treated during 2016-2030. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusions<\/h3>\n\n\n\n<p>Elimination of HCV in Greece by 2030 necessitates great improvements in primary prevention, implementation of large screening programs and high treatment coverage.<\/p>\n\n\n\n<p><strong>Countries:<\/strong> Greece<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. J Gastroenterol Hepatol. 2017 Feb;32(2):466-472. doi: 10.1111\/jgh.13485. PMID: 27403912. Summary Background &amp; Aim The treatment of hepatitis C (HCV) with interferon (IFN)-free Direct-Acting [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,10],"publication-author":[],"class_list":["post-2612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hcv"],"acf":[],"_links":{"self":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/comments?post=2612"}],"version-history":[{"count":4,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2612\/revisions"}],"predecessor-version":[{"id":3409,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/posts\/2612\/revisions\/3409"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/media\/3322"}],"wp:attachment":[{"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/media?parent=2612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/categories?post=2612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/tags?post=2612"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/wp-json\/wp\/v2\/publication-author?post=2612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}